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Hepatobiliary manifestations occur quite frequently
in patients suffering from chronic ulcerative colitis
and Crohn’s disease and carry with them consider-
able morbidity and mortality. Although the true
incidence is difficult to determine, clinically sig-
nificant hepatobiliary disease occurs in 5%-10% of
patients. At the present moment, the aetiology and
pathogenesis of inflammatory bowel disease and its
systemic manifestations remains speculative. For
those hepatobiliary manifestations that respond to
therapy of the underlying bowel disease, medical
and/or surgical therapy must be aggressively pur-
sued. More urgent research is required towards
understanding the underlying cause(s) of the pri-
mary bowel disease and its systemic manifestations
in order to improve the overall management of this
condition.
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INTRODUCTION
Chronic ulcerative colitis (CUC) and Crohn’s
disease (CD), though chiefly effect the gastro-
intestinal tract, are frequently associated with a
wide array of extraintestinal manifestations
(EIM), the incidence of which varies between
25% and 36% [1-3]. Hepatobiliary manifesta-
tions are amongst the most common EIM asso-
ciated with inflammatory bowel disease (IBD).
They not only complicate the management of the
primary disease but also contribute significantly
to mortality and morbidity. Even before CUC
was recognized as a clinical entity, fatty liver
changes with diffuse colonic ulceration were de-
scribed as early as 1874 by Thomas [4] which
were confirmed by Lister in 1889 [5] who re-
ported a patient with CUC and secondary dif-
fuse hepatitis. Further evidence of association
between CUC and hepatic involvement emerged
from an autopsy study [6]. Although initial
studies failed to show any association between
CD and hepatobiliary disease, it soon became
apparent that liver and biliary tract involvement
occurs with equal frequency in patients with
CD and CUC [7].
Although the prevalence of hepatobiliary dis-
ease in patients with IBD varies widely in differ-
ent series from 2%-95%, clinically significant
liver disease occurs in only 5%- 10% of patients
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[8] (Tab. I). Such a discrepancy between the
various series occurs because of a number of
factors which include (a) on how aggressively
diagnostic studies are pursued; (b) the number
of patients included with mild, moderate and
severe disease; (c) whether the disease was ac-
tive or in remission and (d) the type of bowel in-
volvement i.e., extensive or limited. There is no
consistent temporal relationship between the
onset of symptoms and hepatobiliary abnorm-
alities [7]. On average, CUC is present for
approximately 8 years before the hepatic ab-
normalities become apparent [7]. The onset of
symptoms may precede, follow or occur at the
time of exacerbation of bowel disease. Asso-
ciated hepatic conditions range from those
which are little more than laboratory abnormal-
ities, to those that are life-threatening. An inter-
esting observation noted in patients with CD is,
if the disease is restricted to the small bowel,
hepatic involvement is rare.
Because the etiology and pathogenesis of IBD
and the associated hepatobiliary complications
remain elusive and speculative in the large
part, it remains unresolved if these manifesta-
tions represent the systemic nature of the IBD
or whether they truly are complications of the
colitis.
FATTY LIVER (HEPATIC STEATOSIS)
Fatty liver occurs in 15%-80% of patients with
IBD [9]. Patients with severe colitis, fulminant
first attack of colitis and those requiring colect-
omy over the age of 50 have the highest risk of
developing this condition [8]. The incidence,
however, falls to approximately 5% with mild
disease [10]. Numerous factors may contribute
towards this condition including malnutrition,
bacterial metabolites, anemia, protein loss, drugs
such as corticosteroids and tetracycline, chronic
debilitating illness and total parental nutrition.
Histological analysis reveals large fat droplets
within hepatocytes with minimum surrounding
inflammation. Fortunately, fatty liver does not
progress to debilitating liver disease. This is an
asymptomatic condition, although abdominal
examination may reveal hepatomegaly. Treat-
ment of the underlying bowel pathology and
improving general health of the patients is all
that is required. With advances in the treatment
of IBD, the incidence of this condition may be
far less than previously reported.
CHOLELITHIASIS
Cholelithiasis occurs in 4%-34% of patients
with IBD [2, 8,11-13]. It occurs more frequently
in CD than in CUC, and is perhaps more a
secondary complication rather than a systemic
manifestation. In CD, there is a positive correla-
tion between stone formation and location,
extent, and duration of ileal involvement as
well as ileal resection and increased patient age
[2,13-15]. For CUC, total colitis extending to the
caecum poses the greatest risk for gallstones
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[16]. The formation of cholesterol gallstones
stems from the interruption of the normal
enterohepatic circulation of bile acids. Disrup-
tion of the normal enterohepatic circulation re-
sults in depletion of the bile salt pool and the
subsequent secretion of lithogenic bile [17,18].
The mechanism involved in the formation of
radiopaque pigmented stones is not completely
understood. If the gallstones becomes sympto-
matic, laparoscopic or open cholecystectomy is
the treatment of choice.
CHOLANGIOCARCINOMA/
HEPATOCELLULAR CARCINOMA
Cholangiocarcinoma in association with CUC
was first recognized by Parker and Kendall in
1954 [19]. Since then this relationship between
biliary tract tumors and CUC has been well
established. The reported incidence of cholan-
giocarcinoma in patients with IBD is between
0.4% 1.4%, which is 10 100 times greater than
reported for the general population [9,20-24].
On the other hand, the incidence of CUC in pa-
tients with bile duct cancer is between 6% and
14% [24]. It is more common in men and occurs
in the fourth and fifth decades, about 20 years
earlier than in the general population [8,10,14].
It occurs predominantly in patients with CUC,
but has also been reported in patients with CD.
Most cholangiocarcinomas develop in patients
with preexisting PSC [25]. The greatest risk ap-
pears to be for those CUC patients with pan-
colitis and for those with an average duration
of 15 years of disease [9]. There is no appar-
ent relationship between the development of
cholangiocarcinoma and the activity of bowel
disease as it may develop during prolonged
remission and even following proctocolectomy
[21,22,26,27]. The clinical presentation of cho-
langiocarcinoma is that of progressive chole-
static jaundice. Radiographically, these tumors
may present as polypoid or papillary masses,
as rapidly progressive strictures, or as annular
constricting lesions with proximal bile duct
dilatation. Common sites of involvement are
large biliary ducts or the bifurcation of the
intrahepatic ducts. Endoscopic retrograde cho-
langiopancreatography (ERCP) or percutaneous
transhepatic cholangiography (PTC) will de-
monstrate the majority of these lesions, while
laparotomy may be reserved where diagnosis is
in doubt. A retrospective study suggests that
the measurement of tumor associated antigen
CA 19-9, may be promising for the detection
of cholangiocarcinoma complicating PSC [28].
The tumour usually pursues a progressive course
and prognosis is very poor, with a median sur-
vival of 5 months [29]. Palliative surgery is the
most effective treatment but has little impact
on prolonging the survival [8]. Similarly the
results of orthotopic liver transplantation has
been disappointing due to early recurrences [30].
Fibrolamellar hepatocellular carcinoma has
recently been diagnosed in two patients with
CUC and PSC [31,32]. Both of these patients
were free of cirrhosis. One of these patients re-
ceived liver transplantation but died of tumor
recurrence [32].
LIVER CIRRHOSIS
Cryptogenic liver cirrhosis occurs in approxi-
mately 1-5% of patients with hepatic abnor-
malities and IBD [33,34]. It is more frequently
seen in extensive ulcerative colitis or Crohn’s
colitis as compared to Crohn’s ileitis. Auto-
immune Chronic Active Hepatitis (AICAH), peri-
cholangitis and PSC are important risk factors
[9]. In some patients who have received multiple
blood transfusions, hepatitisC maybe a causative
agent. The treatment of choice for end stage liver
disease is liver transplantation. Central portosys-
temic shunts must be avoided as not only do they
increase perioperative mortality rates but they
also make liver transplantation technically more
challenging [8]. Patients may present with signs
and symptoms of end-stage liver disease such as
jaundice, ascites, encephalopathy, spontaneous
bacterial peritonitis and gastric and oesophageal366 M.I. MEMON et al.
bleeding. Oesophageal variceal bleeding can
easily be treated using endoscopic banding,
sclerotherapy or transjugular intrahepatic
portosystemic shunting (TIPS). The majority of
authors report that neither medical or surgical
treatment of IBD has any effect on the natural
history of cirrhosis [35]. Eade et al. [36] none-
theless did show arrest or regression of fibrosis
in the majority of patients after colectomy.
AUTOIMMUNE CHRONIC ACTIVE
HEPATITIS (AICAH)
Autoimmune chronic active hepatitis occurs in
1% of cases of IBD, mainly in CUC [3, 37]. Con-
versely, the incidence of IBD in patients with
AICAH varies between 4% and 30% [35]. There
is no relation between the activity of the
hepatitis and the severity or activity of colitis.
Olsson and Hulten [38], however, have reported
significant improvement in AICAH following
colectomy. Factors implicated in the causation
of AICAH include blood transfusion, ethanol
abuse, PSC and autoimmune phenomenon with
genetic predisposition [9]. Progression to post-
necrotic cirrhosis may occur. There is some
evidence that patients with severe AICAH with
CUC respond less favourably to treatment com-
pared to their counterparts without CUC [39].
HEPATIC AMYLOIDOSIS
patients may also develop renal amyloidosis
resulting in renal impairment which may cul-
minate into renal failure in the post-operative
period [9]. The prognosis of these patients is gen-
erally poor.
HEPATIC ABSCESS
Pyogenic liver abscess occurs in 0.3% of patients
with CD. The abscesses are frequently multiple
and carry a high mortality [2]. A number of
mechanisms have been proposed including (a)
seeding from the portal vein; (b) direct exten-
sion from intra-abdominal abscesses; (c) indi-
rect complications from CD such as acalculous
cholecystitis or enteric fistulas; and (d) from
sepsis occurring in malignancies metastasizing
to the liver [8, 9]. Patients may present with right
upper quadrant pain, pyrexia, nausea, vomiting,
hepatomegaly, jaundice, and right subcostal
tenderness. The diagnosis can be made on the
basis of history, clinical examination, cultures,
ultrasonography, computerized tomography
(CT), magnetic resonance imaging (MRI) and
radionuclide scanning [9]. Streptococcus, Kleb-
siella, and E. Coli are the three most common
organisms identified and treatment includes
broad spectrum antibiotics combined with per-
cutaneous drainage under ultrasound or CT
guidance. Surgical drainage is reserved for pa-
tients who deteriorate or who do not respond to
the above regimen within two weeks.
Hepatic amyloidosis occurs in less than 1% of
patients with IBD, and the majority of these
patients have CD [8,10,14]. There is no relation-
ship between the site of bowel involvement and
occurrence of amyloidosis [40]. It usually in-
volves the media of the branches of the hepatic
artery in the portal triad and, to a lesser extent,
the portal venules and bile ductules [40,41].
Clinically patients may present with hepatome-
galy. Regression has been reported following
the resection of inflamed bowel [42,43]. These
HEPATIC GRANULOMAS
Hepatic granulomas are rare findings occurring
commonly in patients with CD, although they
have been described in patients with CUC.
Usually asymptomatic, they may present with
fever, hepatomegaly and jaundice. They may
cause modest elevation in serum alkaline phos-
phatase (50% of cases) and may resolve when
the diseased bowel is resected [33, 44, 45].HEPATOBILIARY MANIFESTATIONS 367
PRIMARY SCLEROSING CHOLANGITIS
Primary Sclerosing Cholangitis (PSC) is a
chronic, slowly progressive, cholestatic liver
disease of unknown pathology, most commonly
occurring in young men between the ages of
20 and 40 years [46,47]. It is characterized by
progressive chronic stenosing and fibrosing
inflammation of both the intrahepatic and extra-
hepatic biliary tree. Generally accepted diag-
nostic criteria for PSC are outlined in Table II.
Primary sclerosing cholangitis occurs in 4%-
10% of patients with CUC [9,48,49] and 3.4%
of patients with CD [50]. However, when CD
involves the large bowel, the incidence of PSC
increases to 9%, a rate similar to CUC [51]. On
the other hand between 54% and 100% of PSC
patients have IBD [47,52-56].
Currently the etiopathogenesis of both PSC
and IBD remains speculative. Present evidence
however suggests that PSC is an autoimmune
disorder, where immunologic factors triggered
by a virus or bacteria in genetically susceptible
individuals are thought to damage bile duct
epithelial cells [57]. Other factors that have been
implicated in the etiology of PSC include en-
vironmental toxins, hepatic copper, viral in-
fections (hepatitis A,B,C,D, cytomegalovirus, and
reovirus), portal bacteremia, absorbed colonic
toxins, toxic bile acids, genetic predisposition
(HLA-B8, HLA-DR2, HLA-DR3 and HLA-
DRw52A), ischemic arteriolar injury and altered
cellular and humoral immunological responses
[47,58-66].
There is no relationship between PSC and the
onset, duration, activity, or extent ofCUC [2, 67-
69]. It can even present years after proctocolect-
omy [67-70]. Although most patients have no
hepatobiliary symptoms or signs during the
early phase of the disease, others will present
with malaise, fatigue, jaundice, weight loss, right
upper quadrant abdominal pain, hepatomegaly,
pruritus, acute cholangitis and/or portal hyper-
tension. Diagnosis is based on history, laboratory
investigations, ERCP or PTC and liver biopsy.
To date there is no effective treatment available
which can reverse or halt the progression of
PSC. In desperation there has been a surge of in-
terest in the use of ursodeoxycholic acid in PSC
[47, 71]. Ursodeoxycholic acid (UDCA) has been
investigated on the grounds that it: (a) is mini-
mally toxic, (b) replaces the bile acid pool with
a less toxic bile (compared to lithocholic acid),
(c) decreases the expression of class I antigens
on the biliary epithelium, thereby modifying
immunological responses and (d) improves
biochemical indices as well as histopathologi-
cal features. In two randomized trials [72,73],
however, the use of UDCA failed to show any
improvement in clinical parameters, histology,
or time to treatment failure or liver transplanta-
tion. Symptomatic treatments for PSC include
cholestyramine, UDCA or/and antihistamines
for pruritus, replacement of fat soluble vitamins
(A,D,E,K), calcium and vitamin D for meta-
bolic bone disease, ERCP, endoscopic sphinc-
terotomy and stone extraction for obstructed
juandice and cholangitis secondary to choledo-
cholithiasis, antibiotics for bacterial cholangitis,
endoscopic dilatations and stents for bile duct
strictures, and cholecystectomy for gallstones.
A number of other therapies and strategies are
also relevant to IBD complicated by PSC. First of
all, the mainstay for end stage liver disease in a
selected group of patients is liver transplanta-
tion. In the event of variceal bleeding, most
TABLE II Criteria for diagnosing PSC
Cholestatic biochemical profile i.e., alkaline phosphatase level greater than 1.5 fold over the normal limits for 6 months or
more
Generalized beading, stricturing or irregularity of the biliary system based on cholangiography
Interlobular and septal bile duct fibrosis and obliteration on liver biopsy in the absence of other causes of chronic liver disease
Exclude other cause of liver disease such as biliary calculi, biliary tract surgery, congenital biliary conditions, AIDS associated
cholangiopathy, ischaemic stricturing, biliary neoplasms, chemical hepatitis, PBS or CAH368 M.I. MEMON et al.
surgeons do not recommend hepatobiliary shunt
surgery because it increases the risk of bacterial
cholangitis and may increase the perioperative
mortality of a potential liver transplantation [37].
Sclerotherapy is considered a treatment of choice
in these patients. If variceal sclerotherapy fails
to control the bleeding, transjugular intrahepatic
portosystemic shunt (TIPS) should be consider-
ed as a bridge to liver transplantation [8]. Liver
transplantation is ultimately recommended for
patients with variceal bleeding or known varices
with hypersplenism, rising serum bilirubin
levels, decreased synthetic liver function, recur-
rent cholangitis, repeated radiological or endo-
scopic procedures to maintain the ductal patency
or spontaneous bacterial peritonitis. Parastomal
bleeding can be another troublesome source of
problems in these patients after colectomy and
ileostomy [74]. The complication of parastomal
bleeding can be prevented by performing an
ileoanal anastomosis, or ileal pouch anal anasto-
mosis rather than fashioning an ileal stoma, in
patients undergoing panproctocolectomy for
IBD in the presence of PSC [74-76]. Primary
sclerosing cholangitis seems to be an additional
risk factor for the development of colon cancer
in those with long standing CUC [72,77]. If
carcinoma or precancerous lesions develop in
the colon, a proctocolectomy is indicated.
PERICHOLANGITIS OR SMALL DUCT
PRIMARY SCLEROSING CHOLANGITIS
Pericholangitis or small duct primary sclerosing
cholangitis is a subset of PSC which is diagnosed
on the basis of liver biopsy in the presence of
a normal cholangiogram. It occurs in 30% of
patients with IBD, is usually benign, and its
course often parallels the bowel disease activ-
ity and severity [33, 78]. It is now believed that
pericholangitis represents a continuum in the
spectrum of PSC [79]. The majority of cases
resolve with residual mild periductal fibrosis,
some may progress to a chronic phase or to PSC
or to cirrhosis [7, 79, 80].
CONCLUSION
Hepatobiliary manifestations are an important
cause of morbidity and mortality in patients
with IBD. On one hand the presence of some of
these manifestations may provide a justification
for bowel resection, but on the other hand their
presence may predict a complex and compli-
cated perioperative recovery. Although some
hepatobiliary complications are obviously di-
rectly related to local disease complications,
such as stone formation or liver abscesses, or
related to therapeutic side-effects, such as drug-
induced liver steatosis, others appear to be sys-
temically-mediated. Frustratingly, the aetiology
and pathogenesis of IBD and its systemic
manifestations including hepatobiliary disease
remains mysterious. For now, we must settle
for a more practical approach to understanding
the relationship between hepatobiliary manifes-
tations and bowel disease activity if and when it
exists (Tab. III). For those hepatobiliary manifes-
tations that respond to therapy of the under-
lying bowel disease, medical and/or surgical
TABLE III Hepatobiliary manifestations of IBD and their relationship to bowel activity and bowel surgery
Hepatobiliary manifestations Relationship to bowel activity Relationship to bowel surgery
Hepatic Steatosis Usually parallels May resolve
Cholelithiasis Unrelated May deteriorate
Pericholangitis Unrelated No change
Primary sclerosing cholangitis Unrelated No change
Autoimmune chronic active hepatitis Unrelated May improve
Cryptogenic cirrhosis Unrelated No change
Adenocarcinoma of bile ducts Unrelated No change
Hepatic amyloidosis Unrelated May resolve*
Hepatic granulomas Unrelated May resolveHEPATOBILIARY MANIFESTATIONS 369
therapy must be aggressively pursued. The re-
sponse of a given hepatobiliary manifestation
to surgery at least provides a framework for con-
sidering the role of the surgeon in the manage-
ment of these often difficult clinical problems.
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